
Dgbrad 7.5mg Tablet
Marketer
Daxia Healthcare
Salt Composition
Ivabradine (7.5mg)
Overview Dgbrad 7.5mg Tablet
Cardoxin 7.5mg tablets effectively manage angina pectoris (chest pain stemming from heart issues) and persistent congestive heart failure. Its mechanism involves enhancing cardiac efficiency by reducing heart rate, thus alleviating chest discomfort and minimizing hospital readmissions for heart failure patients. Dosage is tailored to the specific condition. Given the typically lifelong nature of angina and heart failure treatment, discontinuation requires physician consultation. Consistent daily administration with food is recommended. Accidental overdose may cause pronounced bradycardia, fatigue, and shortness of breath, necessitating immediate medical attention. Common, usually transient, adverse effects include visual scintillations, bradycardia, hypertension, atrial fibrillation, vertigo, blurred vision, and electrocardiographic abnormalities. Serious reactions like syncope and significant arrhythmias mandate prompt medical intervention. Refrain from driving until the drug's effects are ascertained. Contraindicated in patients with severe hepatic impairment, pre-existing bradycardia, arrhythmias, severe hypotension, or recently exacerbated heart failure. Interactions exist with certain antihypertensives, antifungals, and antiretrovirals. Avoid use during pregnancy, attempts at conception, or breastfeeding.
Uses of Dgbrad 7.5mg Tablet
Managing angina pectoris (chest pain from heart disease) and heart failure.
Major Benefits of Dgbrad 7.5mg Tablet:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the 7.5mg Dgbrad tablet whole; avoid chewing, crushing, or breaking it. Administer this medication with food.
Common Side effects of Dgbrad 7.5mg Tablet:
- Slow heart rate
- Luminous phenomena (Enhanced brightness)
- High blood pressure
- Atrial fibrillation
- Dizziness
- Blurred vision
- ECG changes
How to use Dgbrad 7.5mg Tablet:
Consume this medication precisely as directed by your physician, adhering to both the prescribed dosage and treatment period. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. The 7.5mg Dgbrad tablet should be administered with a meal.
How Dgbrad 7.5mg Tablet works:
Cardiostat 7.5mg tablets decrease cardiac rate, thereby diminishing myocardial oxygen demand and enhancing overall cardiac efficiency.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Dgbrad 7.5mg Tablet may pose safety risks; seek medical advice before combining them.
PregnancyUNSAFE
The use of Dgbrad 7.5mg Tablets is strongly contraindicated during pregnancy. Pregnant individuals should consult their physician, as research in both animal and human studies has revealed substantial adverse effects on fetal development.
Breast feedingUNSAFE
The medication Dgbrad 7.5mg Tablet is contraindicated for breastfeeding mothers due to potential infant toxicity.
DrivingUNSAFE
Taking Dgbrad 7.5mg tablets might impair driving ability. This medication can induce temporary visual disturbances, primarily characterized by phosphenes. The potential for such light flashes should be considered, particularly during nighttime driving.
KidneyCAUTION
Caution is advised when prescribing Dgbrad 7.5mg Tablets to individuals with severely impaired kidney function. Dosage modification may be necessary. Physician consultation is recommended. Data regarding the use of Dgbrad 7.5mg Tablets in patients with severe renal impairment is limited.
LiverCAUTION
Individuals with hepatic impairment should exercise caution when taking Dgbrad 7.5mg tablets, as dose modification may be necessary. Consultation with a physician is advised. Dgbrad 7.5mg tablets are contraindicated in patients exhibiting severe liver dysfunction.
What if you forget to take Dgbrad 7.5mg Tablet :
Omit any missed Dgbrad 7.5mg Tablet dose and resume your usual medication regimen. Avoid taking a double dose.
Facts to Know About Dgbrad 7.5mg Tablet
| Label | Value |
|---|---|
| Chemical Classification | Benzazepine compound |
| Developing Habits | No. |
| Type of Treatment | Heart |
| Behavior Class | Sodium channel blockers targeting the sinoatrial node's I<sub>f</sub> current |
